Net Pals Net Pals
Resultados de la búsqueda
Ver todos los resultados
  • Participar
    Iniciar sesión
    Registrarse
    Buscar
    Night Mode

Buscar

Descubre nuevas personas, crear nuevas conexiones y hacer nuevos amigos

  • Noticias Feed
  • EXPLORE
  • Páginas
  • Grupos
  • Eventos
  • Reels
  • Blogs
  • Mercado
  • Ofertas
  • Empleos
  • Entradas
  • Blogs
  • Usuarios
  • Páginas
  • Grupos
  • Eventos
  • anjushinde13 agregó una foto Health
    2026-07-22 10:16:31 - Translate -
    Common Drugs Use In Ophthalmology Market Competitive Landscape Overview
    The Common Drugs Use In Ophthalmology Market continues to expand as ophthalmologists, optometrists, and eye care specialists increasingly rely on established pharmacological agents to manage the growing spectrum of ocular diseases affecting vision and quality of life. With common ophthalmic drugs including anti-VEGF agents, prostaglandin analogs, corticosteroids, antibiotics, anti-allergy...
    0 Commentarios 0 Acciones 371 Views 0 Vista previa
    Please log in to like, share and comment!
  • mahir007 agregó una foto Other
    2026-11-18 10:01:12 - Translate -
    Aflibercept Market Size, Share, Trends & Forecast 2033
    Executive Summary Aflibercept Market Size and Share Analysis ReportCAGR ValueData Bridge Market Research analyses that the aflibercept market which was USD 8,343.15 million in 2022, and would rocket up to USD 13,911.94 million by 2030, and is expected to undergo a CAGR of 5.40% during the forecast period. This indicates that the market value. “Hospitals” dominates the end user...
    0 Commentarios 0 Acciones 5 Views 0 Vista previa
    Please log in to like, share and comment!
  • EthanWalker agregó una foto Other
    2026-10-23 22:16:07 - Translate -
    Alvotech (ALVO) files first known Eylea 8 mg biosimilar application in Europe
    Alvotech and Advanz Pharma sent AVT29 to the European Medicines Agency on 14 October 2026 as a line extension to Mynzepli, the Eylea 2 mg biosimilar. Alvotech (ALVO) and its partner Advanz Pharma submitted AVT29 to the European Medicines Agency on 14 October 2026, according to a company release issued the same day. AVT29 is a proposed biosimilar to Eylea 8 mg, the higher-dose form of...
    0 Commentarios 0 Acciones 2K Views 0 Vista previa
    Please log in to like, share and comment!
© 2026 Net Pals Spanish
English Arabic French Spanish Portuguese Deutsch Turkish Dutch Italiano Russian Romaian Portuguese (Brazil) Greek
About Términos Privacidad Cookies Acceptable Use Contact Us Directorio